Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.  |
AIDS TREATMENT NEWS - August 23, 2004
John S. James
Two large clinical trials on treating hepatitis C in patients also infected with HIV(1,2) were published July 29, 2004, in the New England Journal of Medicine. The results were already known because they had been presented at the 2004 Retroviruses conference (abstracts #110 and #112). The new publication provides much more detail -- and more credibility when it is necessary to advocate for payment from insurance companies or public agencies (including prisons) for patients with HIV who need treatment for hepatitis C (many who have hepatitis C do not need treatment, at least not immediately). Often two articles in peer-reviewed journals are demanded by payers to establish that a treatment is standard of care (meaning that refusing to consider it is probably malpractice). Now we have the two articles -- in the medical journal usually considered the most prestigious in the U.S.
An August 4 summary by AIDS writer Liz Highleyman, "Final APRICOT and ACTG 5071 HIV/HCV Coinfection Results Published," is available at Aidsmap, http://www.aidsmap.com (try searching for APRICOT, and click on the "Final APRICOT..." paper). This is a place to start for understanding these trials and what they mean for treatment of hepatitis C.
An editorial in the Perspective section of the same issue of New England Journal of Medicine, "Treating Hepatitis C in 'Difficult-to-Treat' Patients" includes important background about the disease, causes of treatment failures, and prospects for major improvement in hepatitis C treatment over the next five to ten years. The text of this editorial is available at
http://www.natap.org/2004/HCV/072904_01.htm
The abstracts of the two studies are available at
http://content.nejm.org/content/vol351/issue5/index.shtml
References
| 1. | Torriani FJ, Rodriguez-Torres M, Rockstroh JK, and others. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients. N Engl J Med. 2004 Jul 29;351(5):438-50. [This is the APRICOT study.] |
| 2. | Chung RT, Andersen J, Volberding P, and others. Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirfin for Chronic Hepatitis C in HIV-Coinfected Persons. N Engl J Med. 2004 Jul 29;351(5):451-9. [This is the ACTG A5071 study.] |
040823
ATN040803
Copyright © 2004 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .